A Phase 2 Study to Evaluate the Efficacy and Safety of ENN0403 in Subjects with DME

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 12, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

February 28, 2026

Conditions

Diabetic Macular Edema (DME)

Interventions

DRUG

ENN0403, low dose

ENN0403 capsules will be orally administered once a day for 12 weeks.

DRUG

ENN0403, high dose

ENN0403 capsules will be orally administered once a day for 12 weeks.

Trial Locations (1)

RECRUITING

Tianjin Medical University Eye Hospital, Tianjin